Vertical Pharms Drug Patent Portfolio
Vertical Pharms owns 1 orange book drug protected by 21 US patents Given below is the list of Vertical Pharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11672738 | Apparatus and methods for dispensing oral transmucosal dosage forms | 02 Feb, 2038 | Active |
US8945592 | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same | 29 Jul, 2031 | Active |
US8202535 | Small-volume oral transmucosal dosage forms | 22 Oct, 2030 | Active |
US8865743 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 22 Oct, 2030 | Active |
US10896751 | Storage and dispensing devices for administration of oral transmucosal dosage forms | 16 Mar, 2030 | Active |
US11676691 | Storage and dispensing devices for administration of oral transmucosal dosage forms | 16 Mar, 2030 | Active |
US12033733 | Storage and dispensing devices for administration of oral transmucosal dosage forms | 16 Mar, 2030 | Active |
US8574189 | Storage and dispensing devices for administration of oral transmucosal dosage forms | 16 Mar, 2030 | Active |
US10245228 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 05 Jan, 2027 | Active |
US10342762 | Small-volume oral transmucosal dosage forms | 05 Jan, 2027 | Active |
US10507180 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 05 Jan, 2027 | Active |
US8226978 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 05 Jan, 2027 | Active |
US8231900 | Small-volume oral transmucosal dosage | 05 Jan, 2027 | Active |
US8252328 | Bioadhesive drug formulations for oral transmucosal delivery | 05 Jan, 2027 | Active |
US8252329 | Bioadhesive drug formulations for oral transmucosal delivery | 05 Jan, 2027 | Active |
US8535714 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 05 Jan, 2027 | Active |
US8778393 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 05 Jan, 2027 | Active |
US8778394 | Small-volume oral transmucosal dosage forms | 05 Jan, 2027 | Active |
US8865211 | Bioadhesive drug formulations for oral transmucosal delivery | 05 Jan, 2027 | Active |
US9320710 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 05 Jan, 2027 | Active |
US9744129 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | 05 Jan, 2027 | Active |
Latest Legal Activities on Vertical Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vertical Pharms.
Activity | Date | Patent Number |
---|---|---|
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Apr, 2024 | US10896751 |
Payment of Maintenance Fee, 12th Year, Large Entity | 28 Feb, 2024 | US8252329 |
Payment of Maintenance Fee, 12th Year, Large Entity | 28 Feb, 2024 | US8252328 |
Payment of Maintenance Fee, 12th Year, Large Entity | 31 Jan, 2024 | US8231900 |
Payment of Maintenance Fee, 12th Year, Large Entity | 24 Jan, 2024 | US8226978 |
Email Notification
Critical
| 09 Jan, 2024 | US8778393 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 09 Jan, 2024 | US8778393 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Dec, 2023 | US8778393 |
Email Notification
Critical
| 20 Dec, 2023 | US8778393 |
Mail O.P. Petition Decision | 19 Dec, 2023 | US11676691 |
Email Notification
Critical
| 19 Dec, 2023 | US11676691 |
Payment of Maintenance Fee, 12th Year, Large Entity | 19 Dec, 2023 | US8202535 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Dec, 2023 | US8778394 |
Email Notification
Critical
| 18 Dec, 2023 | US8778394 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Dec, 2023 | US8865211 |
Vertical Pharms's Family Patents
Vertical Pharms drugs have patent protection in a total of 19 countries. It's US patent count contributes only to 38.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Vertical Pharms Drug List
Given below is the complete list of Vertical Pharms's drugs and the patents protecting them.
1. Dsuvia
Dsuvia is protected by 21 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11672738 | Apparatus and methods for dispensing oral transmucosal dosage forms |
02 Feb, 2038
(13 years from now)
| Active |
US8945592 | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
29 Jul, 2031
(6 years from now)
| Active |
US8202535 | Small-volume oral transmucosal dosage forms |
22 Oct, 2030
(6 years from now)
| Active |
US8865743 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
22 Oct, 2030
(6 years from now)
| Active |
US10896751 | Storage and dispensing devices for administration of oral transmucosal dosage forms |
16 Mar, 2030
(5 years from now)
| Active |
US11676691 | Storage and dispensing devices for administration of oral transmucosal dosage forms |
16 Mar, 2030
(5 years from now)
| Active |
US12033733 | Storage and dispensing devices for administration of oral transmucosal dosage forms |
16 Mar, 2030
(5 years from now)
| Active |
US8574189 | Storage and dispensing devices for administration of oral transmucosal dosage forms |
16 Mar, 2030
(5 years from now)
| Active |
US10245228 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
05 Jan, 2027
(2 years from now)
| Active |
US10342762 | Small-volume oral transmucosal dosage forms |
05 Jan, 2027
(2 years from now)
| Active |
US10507180 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
05 Jan, 2027
(2 years from now)
| Active |
US8226978 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
05 Jan, 2027
(2 years from now)
| Active |
US8231900 | Small-volume oral transmucosal dosage |
05 Jan, 2027
(2 years from now)
| Active |
US8252328 | Bioadhesive drug formulations for oral transmucosal delivery |
05 Jan, 2027
(2 years from now)
| Active |
US8252329 | Bioadhesive drug formulations for oral transmucosal delivery |
05 Jan, 2027
(2 years from now)
| Active |
US8535714 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
05 Jan, 2027
(2 years from now)
| Active |
US8778393 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
05 Jan, 2027
(2 years from now)
| Active |
US8778394 | Small-volume oral transmucosal dosage forms |
05 Jan, 2027
(2 years from now)
| Active |
US8865211 | Bioadhesive drug formulations for oral transmucosal delivery |
05 Jan, 2027
(2 years from now)
| Active |
US9320710 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
05 Jan, 2027
(2 years from now)
| Active |
US9744129 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
05 Jan, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dsuvia's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List